Apellis Pharmaceuticals Stock Investor Sentiment
| APLS Stock | USD 24.14 0.01 0.04% |
Slightly above 55% of Apellis Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Apellis Pharmaceuticals suggests that many traders are impartial. Apellis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apellis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 45
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Apellis Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Apellis Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Apellis Historical Sentiment
Although Apellis Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Apellis, such as negative comments on social media and news outlets, may cause fear in the market and push Apellis Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Apellis.
Apellis |
Apellis Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Apellis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Apellis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Apellis Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. That information is available publicly through Apellis media outlets and privately through word of mouth or via Apellis internal channels. However, regardless of the origin, that massive amount of Apellis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.
Apellis Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of tradable shares by Jeffrey Eisele of Apellis Pharmaceuticals at 33.09 subject to Rule 16b-3 | 12/23/2024 |
2 | Acquisition by Chan Gerald of 11199 shares of Apellis Pharmaceuticals at 31.91 subject to Rule 16b-3 | 12/31/2024 |
3 | Acquisition by Dunlop A. Sinclair of 6267 shares of Apellis Pharmaceuticals subject to Rule 16b-3 | 01/03/2025 |
4 | Insider Trading | 01/08/2025 |
5 | Disposition of 1096 shares by Chopas James George of Apellis Pharmaceuticals at 30.4255 subject to Rule 16b-3 | 01/22/2025 |
6 | Apellis Pharmaceuticals, Inc. General Counsel David O. Watson Sells 3,323 Shares | 01/23/2025 |
7 | Disposition of 365 shares by Mark Delong of Apellis Pharmaceuticals at 29.5236 subject to Rule 16b-3 | 01/29/2025 |
8 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 02/04/2025 |
9 | Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli for C3G and Primary IC-MPGN | 02/20/2025 |
10 | Apellis Pharmaceuticals GAAP EPS of -0.29 beats by 0.10, revenue of 212.5M beats by 14.59M | 02/28/2025 |
11 | Disposition of 6667 shares by Watson David O. of Apellis Pharmaceuticals subject to Rule 16b-3 | 03/04/2025 |
12 | Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset JP Morgan Analyst | 03/05/2025 |
13 | The Goldman Sachs Group Cuts Apellis Pharmaceuticals Price Target to 32.00 | 03/06/2025 |
14 | Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. - Defense World | 03/12/2025 |
15 | Disposition of 183 shares by Chopas James George of Apellis Pharmaceuticals at 24.8237 subject to Rule 16b-3 | 03/17/2025 |
16 | JP Morgan Cut Apellis Price Forecasts, Cites Longer Peak Sales Timing For Syfovre | 03/18/2025 |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.